Theriva Biologics Inc.
$ 0.20
1.52%
27 Feb - close price
- Market Cap 7,137,700 USD
- Current Price $ 0.20
- High / Low $ 0.20 / 0.18
- Stock P/E 0.10
- Book Value 0.65
- EPS 2.06
- Next Earning Report 2026-03-05
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.29 %
- ROE -1.67 %
- 52 Week High 1.50
- 52 Week Low 0.16
About
Theriva Biologics Inc., a clinical-stage company, develops therapies to treat diseases in areas of high unmet need. The company is headquartered in Rockville, Maryland.
Analyst Target Price
$7.00
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-12 | 2025-08-11 | 2025-05-05 | 2025-03-24 | 2024-11-11 | 2024-08-13 | 2024-05-07 | 2024-03-25 | 2023-11-13 | 2023-08-08 | 2023-05-11 | 2023-03-30 |
| Reported EPS | -0.45 | -1.93 | -1.55 | -11.49 | -6.8107 | -10.75 | -0.3 | -0.34 | -0.19 | -0.34 | -0.3 | -0.33 |
| Estimated EPS | -1.13 | -1.08 | -1.56 | -7.22 | -5.25 | -0.28 | -0.34 | -0.41 | -0.37 | -0.36 | -0.32 | -0.33 |
| Surprise | 0.68 | -0.85 | 0.01 | -4.27 | -1.5607 | -10.47 | 0.04 | 0.07 | 0.18 | 0.02 | 0.02 | 0 |
| Surprise Percentage | 60.177% | -78.7037% | 0.641% | -59.1413% | -29.7276% | -3739.2857% | 11.7647% | 17.0732% | 48.6486% | 5.5556% | 6.25% | 0% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-03-05 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: TOVX
2026-02-25 07:53:03
This page provides access to THERIVA BIOLOGICS (TOVX) SEC filings, including annual reports (10-K), quarterly earnings (10-Q), material events (8-K), and insider trading forms. It offers detailed information on the company's clinical-stage programs, capital structure, and corporate actions, with AI-powered summaries highlighting key points. The filings cover topics such as shareholder meetings, restructuring plans, clinical trial data announcements, and offering details, helping investors track the company's regulatory and financial developments.
2026-02-24 21:52:22
Theriva™ Biologics announced that data from its VCN-01 retinoblastoma Phase 1 clinical trial and preclinical data on VCN-01 in combination with topotecan will be presented at the 41st Asia-Pacific Academy of Ophthalmology (APAO) Congress on February 7, 2026. The presentation will cover safety and efficacy of VCN-01 in refractory retinoblastoma patients, as well as the synergistic antitumor activity of its combination with topotecan for treating difficult vitreous seeds. This highlights the company's efforts to address high unmet medical needs in pediatric retinoblastoma patients.
2026-02-24 16:40:00
Theriva™ Biologics has licensed SYN-020, a recombinant bovine intestinal alkaline phosphatase, to Rasayana Therapeutics for development and commercialization in multiple indications. Theriva received an upfront payment and is eligible for up to $38 million in milestones plus royalties. Rasayana Therapeutics, specializing in gut-targeted medicines for chronic inflammatory diseases, will assume all development and commercialization costs for SYN-020, which is poised to enter Phase 2 clinical testing.
2026-02-22 07:53:03
Theriva™ Biologics has licensed SYN-020 to Rasayana Therapeutics for the development and commercialization of the drug for multiple indications. Theriva received an upfront payment of $300,000 and is eligible for up to $38 million in development, regulatory, and sales milestones, plus tiered single-digit royalties. Rasayana Therapeutics will assume all responsibility and costs for SYN-020's development and commercialization, focusing on its potential to address various metabolic and inflammatory disorders.
2026-02-20 12:34:48
Theriva Biologics (TOVX) saw its stock rise 12% in pre-market trading on AMEX following a licensing agreement for SYN-020 with Rasayana Therapeutics. The deal provides Theriva with $300,000 upfront and up to $38 million in milestone payments and royalties, significantly reducing near-term clinical development costs. The stock experienced an extreme volume spike, and Meyka AI assigns it a "HOLD" grade with a projected near-term upside of 144.06%.
2026-02-18 19:15:05
Theriva™ Biologics has out-licensed SYN-020 to Rasayana Therapeutics for development and commercialization for multiple indications. Theriva received an upfront payment of $300,000 and is eligible for up to $38 million in development, regulatory, and sales milestones, plus tiered single-digit royalties. Rasayana will take over all responsibilities and costs for SYN-020, which is designed to address metabolic and inflammatory disorders by improving gut health.
